ArticleCommunications biology2018
IDLV-HIV-1 Env vaccination in non-human primates induces affinity maturation of antigen-specific memory B cells.
Article in Communications biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 34 citations in OpenAlex.
- Sex differences in vaccine-induced immunity in mice immunized with integrase-defective lentiviral vector delivering the SARS-CoV-2 Spike protein.Frontiers in immunology · 2026Article
- Review
- Transient regulatory T cell manipulation is limited by anti-antibody responses in HIV-1 envelope immunized rhesus macaques.iScience · 2025Article
- Convergence and divergence of B cell responses in two HIV-1 Env immunizations in Rhesus macaques.Communications medicine · 2025Article
- Review
- Triple tandem trimer immunogens for HIV-1 and influenza nucleic acid-based vaccines.NPJ vaccines · 2024Article
- A SMART method for isolating monoclonal antibodies from individual rhesus macaque memory B cells.Journal of immunological methods · 2024Article
- Article
- Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases.Signal transduction and targeted therapy · 2023Review
- Establishment, Persistence, and Reactivation of Latent HIV-1 Infection in Renal Epithelial Cells.Journal of virology · 2022Article
- The use of viral vectors in vaccine development.NPJ vaccines · 2022Review
- Safety and efficiency modifications of SIV-based integrase-defective lentiviral vectors for immunization.Molecular therapy. Methods & clinical development · 2021Article
- Novel monkey mAbs induced by a therapeutic vaccine targeting the hepatitis B surface antigen effectively suppress hepatitis B virus in mice.Antibody therapeutics · 2021Article
- Structural and genetic convergence of HIV-1 neutralizing antibodies in vaccinated non-human primates.PLoS pathogens · 2021Article
- Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth.Science (New York, N.Y.) · 2021Article
- Integrase-Defective Lentiviral Vectors for Delivery of Monoclonal Antibodies against Influenza.Viruses · 2020Article
- Immunogenicity, safety, and efficacy of sequential immunizations with an SIV-based IDLV expressing CH505 Envs.NPJ vaccines · 2020Article
- Review
- Proliferation of HIV-infected renal epithelial cells following virus acquisition from infected macrophages.AIDS (London, England) · 2020Article
- Development and Preclinical Evaluation of an Integrase Defective Lentiviral Vector Vaccine Expressing the HIVACAT T Cell Immunogen in Mice.Molecular therapy. Methods & clinical development · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 4 institutions in 2 countries.
Funding
Abstract
HIV continues to be a major global health issue. In spite of successful prevention interventions and treatment methods, the development of an HIV vaccine remains a major priority for the field and would be the optimal strategy to prevent new infections. We showed previously that a single immunization with a SIV-based integrase-defective lentiviral vector (IDLV) expressing the 1086.C HIV-1-envelope induced durable, high-magnitude immune responses in non-human primates (NHPs). In this study, we have further characterized the humoral responses by assessing antibody affinity maturation and antigen-specific memory B-cell persistence in two vaccinated macaques. These animals were also boosted with IDLV expressing the heterologous 1176.C HIV-1-Env to determine if neutralization breadth could be increased, followed by evaluation of the injection sites to assess IDLV persistence. IDLV-Env immunization was associated with persistence of the vector DNA for up to 6 months post immunization and affinity maturation of antigen-specific memory B cells.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.